Biktarvy cost in Mexico runs far lower than the US list price of $4,216 per month, a gap that draws steady attention from US patients comparing prices across markets. SunnyPharma is an independent health education platform serving cost-burdened patients navigating medication access, and this page documents what Biktarvy actually costs at Mexican pharmacies in 2026, why the price differs so sharply from the United States, and the lower-cost US options worth knowing before assuming the Mexican price is the cheapest one available to you.
For most US patients, US-side assistance is cheaper than the Mexican private-pharmacy price. With commercial insurance, the Gilead Advancing Access co-pay coupon typically reduces Biktarvy to $0–$15 per month, and uninsured patients who meet income criteria can receive it at no cost through Gilead’s patient assistance program. This page covers the price comparison; for the full US access picture, see Biktarvy without insurance →
Sources: published Mexican pharmacy pricing (2026); Gilead Sciences WAC (Jan 1, 2026); Gilead Advancing Access (2026). Exchange rate: ~20 MXN/USD (March 2026). Private pharmacy prices vary by location and pharmacy type.
What Biktarvy Costs at Mexican Private Pharmacies
Biktarvy is a brand-name-only medication worldwide — no approved generic equivalent exists in Mexico or any other country. What Mexican private pharmacies dispense is the same Gilead-manufactured product sold in the United States, imported under Mexican health regulations and dispensed by COFEPRIS-licensed pharmacies. Prices reflect import costs, regulatory compliance, pharmacy margins, and MXN/USD exchange rate fluctuations.
Based on published pharmacy pricing as of early 2026, a 30-tablet (one-month) supply of Biktarvy at Mexican licensed private pharmacies ranges from approximately MXN $7,500 to MXN $14,257. At March 2026 exchange rates of roughly 20 Mexican pesos to the US dollar, this translates to approximately $375 to $715 USD — substantially below the US wholesale acquisition cost of $4,216, though still a meaningful monthly cost.
- Certified Farmacias de Alta Especialidad (COFEPRIS-registered): MXN $7,500–$10,000 typical range
- General chain pharmacies in upscale urban areas (e.g. Polanco, Mexico City): MXN $10,000–$14,257 range
- Prices denominated in Mexican pesos; fluctuate with USD/MXN exchange rate
- No authorized generic of Biktarvy exists worldwide — all licensed stock is the Gilead brand product
- Authentic product carries Gilead’s holographic seal, lot number, and expiry date
The variation between pharmacy types is substantial. Certified Farmacias de Alta Especialidad, which specialize in high-cost specialty medications and are registered with COFEPRIS, tend to list more competitive pricing on antiretroviral therapy than standard retail chains. The price difference between a specialty pharmacy and a general chain in a wealthy urban area can exceed MXN $5,000 per month for the same product.
Counterfeit risk in unregulated markets. Gilead Sciences has warned that counterfeit Biktarvy circulates in unregulated markets. Only product dispensed by a pharmacy licensed by COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) — Mexico’s federal health regulatory authority — is verified as the authentic Gilead product. COFEPRIS-licensed pharmacies are legally required to dispense Biktarvy only with a valid prescription from a licensed Mexican physician.
Biktarvy Price Comparison: Mexico vs USA
| Source / Scenario | Monthly Cost (USD) | Notes |
|---|---|---|
| Mexico — Specialty pharmacy | ~$375–$500 | Farmacia de Alta Especialidad, COFEPRIS-registered; MXN $7,500–$10,000 |
| Mexico — Chain pharmacy | ~$500–$715 | General retail chain; MXN $10,000–$14,257 |
| Mexico — Public system (IMSS/ISSSTE/CAPASITS) | $0 | Enrolled Mexican patients |
| USA — List price (WAC) | $4,216 | Gilead wholesale acquisition cost, Jan 1, 2026; few patients pay this directly |
| USA — Commercial insurance + Gilead co-pay coupon | $0–$15 | Most common US scenario for commercially insured patients |
| USA — Medicare Part D (2025 cap) | ≤$167/mo | $2,000 annual out-of-pocket cap; many Medicare patients pay much less |
| USA — Medicaid | $0 | Most Medicaid beneficiaries pay $0 for Biktarvy |
| USA — Uninsured, no assistance | ~$3,874–$4,216 | Cash price range at US retail pharmacies (2026) |
Why Biktarvy Is Cheaper in Mexico Than the US
The price gap between Mexico and the United States is a story about pricing policy, not about the product. The Biktarvy sold in both countries is the identical Gilead-manufactured medication. What differs is how each country’s health system sets the price a patient or institution pays.
Mexico was the first country in Latin America to undertake a large-scale national rollout of Biktarvy, following a landmark 2019 agreement between CENSIDA (Centro Nacional para la Prevención y el Control del VIH/SIDA) and Gilead Sciences in which Gilead agreed to supply Biktarvy at a substantially discounted government purchase price. That national agreement anchors lower domestic pricing across the Mexican market. The United States, by contrast, allows manufacturers to set wholesale list prices for commercial-market medications without direct government price negotiation — producing the $4,216 monthly US list price.
Two further factors keep the US price high: Biktarvy remains under Gilead patent protection, and there is no authorized generic anywhere in the world. With no generic competition and no government price negotiation on the commercial side, the US list price has limited downward pressure. This is why US patients see such a dramatic difference when they compare the Mexican private-pharmacy price to the US list price — and also why US-side assistance programs, rather than the Mexican price, are usually the most relevant cost lever for a US patient.
Free Biktarvy Through Mexico’s Public Health System
For patients enrolled in Mexico’s national health institutions, Biktarvy is provided at no cost as part of the country’s universal HIV treatment program. Mexico’s national HIV response is coordinated by CENSIDA under the Secretaría de Salud. This public-system access is the foundation of why Mexico maintains consistent national-level Biktarvy supply — the same supply that ultimately makes private-pharmacy stock more reliable than in countries without national antiretroviral programs.
The 2019 CENSIDA–Gilead agreement was structured to ensure continuous supply — replacing older multi-pill regimens and simplifying treatment for both treatment-naïve patients and those switching from previous antiretrovirals.
Which Institutions Provide Free Biktarvy
| Institution | Coverage Basis | HIV Treatment Access |
|---|---|---|
| IMSS (Mexican Social Security Institute) | Formal employment-based | Free ART including Biktarvy for enrolled workers and dependents |
| ISSSTE (State Workers’ Social Security) | Federal government employees | Free ART including Biktarvy for enrolled state workers |
| CAPASITS clinics (CENSIDA/Secretaría de Salud) | Uninsured Mexican residents | Free HIV treatment at outpatient centers nationwide |
A legal right regardless of immigration status: Under Mexico’s NOM-010-SSA2-2023 standard for HIV prevention and control, all persons in Mexico — regardless of nationality or immigration status — have the legal right to access HIV health services. Public-system enrollment pathways are designed for Mexican residents and vary by institution.
The Lower-Cost US Options Most Patients Overlook
Before assuming the Mexican price is the cheapest route, it is worth knowing that the United States has several programs that frequently bring Biktarvy below the Mexican private-pharmacy price — often to $0. The dramatic Mexico-vs-US list price gap can obscure the fact that very few US patients actually pay the US list price.
- Gilead Advancing Access co-pay coupon reduces Biktarvy to $0–$15/month for most commercially insured patients.
- Gilead’s patient assistance program provides Biktarvy at no cost to uninsured patients who meet income criteria.
- Medicaid covers Biktarvy at $0 for most beneficiaries; eligibility varies by state.
- Medicare Part D caps annual out-of-pocket prescription costs at $2,000, limiting Biktarvy’s monthly cost for enrolled patients.
- Ryan White / ADAP programs assist many low-income people living with HIV who fall between other coverage options.
Start with US-side assistance. If you have not yet tested US options, Gilead Advancing Access ($0–$15/month for commercially insured; no-cost patient assistance for uninsured patients meeting income criteria) is worth exhausting first. Call 1-800-226-2056 or visit gileadadvancingaccess.com. For full guidance on US-side access, see Biktarvy without insurance →
Frequently Asked Questions
How much does Biktarvy cost in Mexico?
At Mexican private pharmacies, Biktarvy (30 tablets, one month’s supply) costs approximately MXN $7,500 to MXN $14,257, which is roughly $375 to $715 USD at March 2026 exchange rates of ~20 pesos to the dollar. Certified Farmacias de Alta Especialidad registered with COFEPRIS tend to list lower prices than general chain pharmacies. Mexico’s public health system — IMSS, ISSSTE, and CAPASITS clinics under CENSIDA — provides Biktarvy at no cost to enrolled patients.
Why is Biktarvy cheaper in Mexico than in the United States?
The price gap reflects how each country sets drug prices, not a difference in the product. In 2019 Mexico’s national HIV program negotiated a discounted government purchase agreement with Gilead Sciences for a large-scale national Biktarvy rollout, which anchors lower domestic pricing. The United States allows manufacturers to set wholesale list prices without government negotiation, producing a $4,216 monthly US list price. The medication itself is the same Gilead-manufactured product in both markets.
Is there a generic version of Biktarvy?
No. Biktarvy is a brand-name-only medication worldwide, with no approved generic equivalent in Mexico, the United States, or any other country as of 2026. Biktarvy combines bictegravir, emtricitabine, and tenofovir alafenamide, and remains under Gilead Sciences patent protection. Because no authorized generic exists anywhere, all licensed Biktarvy is the Gilead brand product, and price differences between countries reflect pricing policy rather than generic competition.
Is Biktarvy from Mexican pharmacies authentic?
Biktarvy dispensed by pharmacies licensed by COFEPRIS, Mexico’s federal health regulatory authority, is the authentic Gilead-manufactured product. Gilead Sciences has warned that counterfeit versions circulate in unregulated markets. Authentic product carries Gilead’s official labeling, including a lot number, expiry date, and holographic seal. COFEPRIS-licensed pharmacies are legally required to dispense Biktarvy only with a valid prescription.
Does Mexico’s public health system provide Biktarvy for free?
Yes, for enrolled patients in Mexico’s national health institutions. Mexico’s national HIV program, coordinated by CENSIDA, provides antiretroviral therapy including Biktarvy at no cost through IMSS, ISSSTE, and CAPASITS clinics. In 2019, Gilead Sciences signed a discounted government purchase agreement enabling Mexico’s national Biktarvy rollout — the first in Latin America. Under NOM-010-SSA2-2023, all persons in Mexico, regardless of immigration status, have the legal right to HIV health services. Public-system enrollment pathways are designed for Mexican residents.
What is the list price of Biktarvy in the United States?
Biktarvy’s wholesale acquisition cost (WAC), the manufacturer’s list price, is $4,216 per month (30 tablets) as of January 1, 2026, according to Gilead Sciences. WAC is the published list price before any insurance, rebate, or assistance program is applied. Few US patients pay the full WAC directly: most have it reduced through insurance, Medicaid, Medicare Part D out-of-pocket caps, or Gilead’s patient assistance programs.
How much does Biktarvy cost in the US without insurance?
Uninsured US patients paying cash face approximately $3,874 to $4,216 per month at US retail pharmacies in 2026, close to the wholesale list price. However, most uninsured patients do not need to pay this. Gilead’s Advancing Access patient assistance program provides Biktarvy at no cost to uninsured patients who meet income criteria, and many patients qualify for Medicaid. SunnyPharma’s guide to Biktarvy without insurance covers these lower-cost US options in detail.
Why does Biktarvy cost so much in the United States?
US drug prices are set by manufacturers without direct government price negotiation for most medications, unlike countries such as Mexico that negotiate national purchase agreements. Biktarvy is a patent-protected, brand-only HIV medication with no generic competition, which keeps the list price high. The $4,216 monthly US list price reflects this combination of patent protection, no generic alternative, and an absence of government price negotiation for commercial-market pricing.
Does insurance cover Biktarvy in the United States?
Yes. Biktarvy is widely covered by commercial insurance, Medicaid, and Medicare Part D. Commercially insured patients using the Gilead Advancing Access co-pay coupon typically pay $0 to $15 per month. Most Medicaid beneficiaries pay $0. Medicare Part D patients benefit from the $2,000 annual out-of-pocket cap. The main coverage gap affects uninsured patients who fall outside both Medicaid eligibility and Gilead’s patient assistance income limits.
How we reviewed this article:
Ana Goios researched and wrote this article using peer-reviewed clinical literature (Open Forum Infectious Diseases), official Mexican regulatory sources (COFEPRIS, CENSIDA, NOM-010-SSA2-2023 federal standard), Gilead Sciences pricing and patient assistance program documentation, and published Mexican pharmacy pricing data. Dr. Brendan Payne reviewed the medical and pricing content for clinical accuracy and completeness. Pricing data reflects sources available as of March 2026 and was last verified June 2026; figures are subject to exchange rate and pharmacy-level variation.
Read our editorial policy →References
- Gilead Sciences. BIKTARVY (bictegravir, emtricitabine, and tenofovir alafenamide) Prescribing Information. Accessed June 2026.
- Gilead Sciences. BIKTARVY Cost Information. Wholesale Acquisition Cost as of January 1, 2026.
- Gilead Sciences. Gilead Advancing Access — Patient Support Programs. Accessed June 2026.
- Navarrete-Opazo AA et al. Comparative effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide in Mexico. Open Forum Infectious Diseases. 2024.
- Diario Oficial de la Federación (Mexico). NOM-010-SSA2-2023 — Para la prevención y el control de la infección por el Virus de la Inmunodeficiencia Humana. Accessed June 2026.
- Secretaría de Salud, Mexico (CENSIDA). Centro Nacional para la Prevención y el Control del VIH/SIDA — Official Site. Accessed June 2026.
- COFEPRIS. Comisión Federal para la Protección contra Riesgos Sanitarios — Official Site. Accessed June 2026.
- Pan American Health Organization. HIV/AIDS — PAHO/WHO Country Resources. Accessed June 2026.
- Instituto Mexicano del Seguro Social. IMSS — Servicios de Salud Oficial. Accessed June 2026.
- AETC National Coordinating Resource Center. Brand and Generic Names of ARVs in the United States and Mexico. Accessed June 2026.
- Foreign Policy. Mexico Is Setting a Global Example on HIV Treatment. November 2019.